Article
Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.
The New England journal of medicine - 2 Oct 2008
Fätkenheuer Gerd, Nelson Mark, Lazzarin Adriano, Konourina Irina, Hoepelman Andy I M, Lampiris Harry, Hirschel Bernard, Tebas Pablo, Raffi François, Trottier Benoit, Bellos Nicholaos, Saag Michael, Cooper David A, Westby Mike, Tawadrous Margaret, Sullivan John F, Ridgway Caroline, Dunne Michael W, Felstead Steve, Mayer Howard, van der Ryst Elna
Abstract excerpt
BACKGROUND: We conducted subanalyses of the combined results of the Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients (MOTIVATE) 1 and MOTIVATE 2 studies to better characterize the efficacy and safety of maraviroc in key subgroups of patients. METHODS: We analyzed pooled data from week 48 from the two studies according to sex, race or ethnic group, clade, CC chemokine...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.